advertisement
11.4 Prostaglandins (23)
Showing records 1 to 23
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins10313 Enhanced expression of cyclooxygenase-2 in glaucomatous dog eyes
Marshall JL; Stanfield KM; Silverman L; Khan KN
Veterinary Ophthalmology 2004; 7: 59-62
10339 Tonometric changes of latanoprost-induced intraocular pressure reduction after photorefractive keratectomy
Tamburrelli C; Vaiano AS; Salgarello T; Caputo CG; Scullica L
Investigative Ophthalmology and Visual Science 2004; 45: 846-850
10128 The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmologica Scandinavica 2004; 82: 161-165
10133 Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma
Chew PT; Aung T; Aquino MV; Rojanapongpun P; EXACT Study Group
Ophthalmology 2004; 111: 427-434
10129 A 12-week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension
Diestelhorst M; Larsson LI; European Latanoprost Fixed Combination Study Group
British Journal of Ophthalmology 2004; 88: 199-203
10139 Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials
Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA; COSOPT versus XALATAN Study Groups
Acta Ophthalmologica Scandinavica 2004; 82: 42-48
10468 An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension
Feldman RM
Expert Opinion in Pharmacotherapy 2004; 5: 909-921
10132 Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure
Shin DH; Feldman RM; Sheu WP; Fixed Combination Latanoprost/Timolol Study Group
Ophthalmology 2004; 111: 276-282
10134 Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma
Sihota R; Saxena R; Agarwal HC; Gulati V
Archives of Ophthalmology 2004; 122: 185-189
10135 Long-term efficacy and safety of combined topical antiglaucoma therapy: timolol and unoprostone versus betaxolol and unoprostone
Ohtake Y; Tanino T; Kimura I; Mashima Y; Oguchi Y
Nippon Ganka Gakkai Zasshi 2004; 108: 23-28
10150 Effects of prostaglandin F2α, latanoprost and carbachol on phosphoinositide turnover, MAP kinases, myosin light chain phosphorylation and contraction and functional existence and expression of FP receptors in bovine iris sphincter
Ansari HR; Kaddour-Djebbar I; Abdel-Latif AA
Experimental Eye Research 2004; 78: 285-296
10520 A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost
Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
Japanese Journal of Ophthalmology 2004; 48:141-147
10465 Herpes simplex virus genome quantification in two patients who developed herpetic epithelial keratitis during treatment with antiglaucoma medications
Deai T; Fukuda M; Hibino T; Higaki S; Hayashi K; Shimomura Y
Cornea 2004; 23: 125-128
10466 Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure
Dubiner HB; Sircy MD; Landry T; Bergamini MVW; Silver LH; Turner FD; Robertson S; Andrew RM; Weiner A; Przydryga J
Clinical Therapeutics 2004; 26: 84-91
10146 Aqueous humor dynamics in monkeys after topical 8-iso PGE2
Gabelt BT; Seeman JL; Podos SM; Mittag TW; Kaufman PL
Investigative Ophthalmology and Visual Science 2004; 45: 892-899
10143 Hypotensive effect of unoprostone as adjunct to latanoprost during multiple drug therapy for glaucoma
Kobayashi H; Iwakiri R; Kobayashi K; Okinami S
Japanese Journal of Clinical Ophthalmology 2004; 58: 193-197
10147 Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma
Nakamura Y; Morine-Shinjo S; Sakai H; Sawaguchi S
Acta Ophthalmologica Scandinavica 2004; 82: 158-160
10148 Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug
Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
Experimental Eye Research 2004; 78: 767-776
10141 Vasodilatory mechanism of unoprostone isopropyl on isolated rabbit ciliary artery
Yoshitomi T; Yamaji K; Ishikawa H; Ohnishi Y
Current Eye Research 2004; 28: 167-174
10144 The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models
Gordon YJ; Yates KA; Mah FS; Romanowski EG
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 233-245
10142 Canadian study of travatan as replacement therapy (CSTART): switching to travatan can improve long-term care
Klein T
Clinical and Refractive Optometry 2004; 15: 16-21
10145 Corneal neovascularization possibly associated with latanoprost therapy
Orhan M; Kerimoglu H; Irkec M
European Journal of Ophthalmology 2003; 13: 88-90
10149 Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment
Stjernschantz J
Experimental Eye Research 2004; 78: 759-766